QVAR REDIHALER
ICS MDI
Beclomethasone dipropionate · Teva Pharmaceuticals
Active Medication & Mechanism
- Beclomethasone dipropionate ICS40 mcg or 80 mcg per actuation
Pro-drug ICS that is converted to active metabolite beclomethasone-17-monopropionate (17-BMP) in the lungs. Provides potent anti-inflammatory activity, reducing inflammatory cells and mediators in the airways. HFA formulation delivers extrafine particles for enhanced small airway deposition.
FDA-Approved Dosing — Strength × Indication
Strength Regimen Asthma
40 mcg or 80 mcg
Varies by indication — see columns
FDA Approved
Adults (previously on bronchodilators alone) 1 inhalation twice daily → 80–160 mcg Starting dose 40–80 mcg twice daily. Highest recommended dose: 320 mcg twice daily (640 mcg/day).
Adults (previously on ICS) 1–4 inhalations twice daily (based on prior ICS dose) → 80–640 mcg Starting dose 40–320 mcg twice daily depending on prior ICS dose. Highest recommended dose: 320 mcg twice daily (640 mcg/day).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
40 mcg or 80 mcg
Asthma FDA Approved
Adults (previously on bronchodilators alone) 1 inhalation twice daily → 80–160 mcg Starting dose 40–80 mcg twice daily. Highest recommended dose: 320 mcg twice daily (640 mcg/day).
Adults (previously on ICS) 1–4 inhalations twice daily (based on prior ICS dose) → 80–640 mcg Starting dose 40–320 mcg twice daily depending on prior ICS dose. Highest recommended dose: 320 mcg twice daily (640 mcg/day).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute use. Use a SABA.